What Happened?
Richmond, CA-based Sangamo Promoted Prathyusha Duraibabu as Senior Vice President and Chief Financial Officer
About the Company
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.
About the Person
Prathyusha Duraibabu is Senior Vice President and Chief Financial Officer at Sangamo. Previously, Prathyusha held various senior HR leadership roles in the industry.
Info Source
News
Short Profile